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1.1. Epidemiological factors of cancer mortality 
The mortality of cancer has increased dramatically during the last decades. The 
estimated number of new cases each year is expected to rise from 10 million in 2000 to 15 
million by 2020. Some 60% of all these new cases will occur in the less developed parts of 
the world. 
Cancer mortality rate in Hungary is the highest in Europe and an analysis of the past 
40 years has revealed a worsening trend. Apart from the high fat consumption, the insufficient 
intake of vegetables, fruits and smoking could be identified as major, convincing risk factors. 
This background plays a role in the development of mouth and pharynx, esophagus, lung, 
stomach, colon and rectum cancers. Cancer causes every fourth death in Hungary. In spite of 
the recent improvements, the premature death rate among under 65-year old Hungarians is the 
highest in the WHO European Region, for both males and females. The 45–59-year old 
Hungarian population has the highest mortality in the WHO European Region, stagnating for 
males and increasing for females. Hungarians have the highest death rates in the WHO 
European Region for lip, colorectal, laryngeal, tracheal, bronchial and lung cancers. 
Pancreatic and breast cancer mortality are the second and fourth highest in the region, 
respectively. For several cancers, the Hungarian rates are either stagnating (skin, liver and 
oesophageal) or increasing (colorectal, lip and pancreatic). 
 
1.2. Oral cancers 
Oral cancer holds the eighth position in the cancer incidence worldwide, but there is 
epidemiologic variation in various geographic regions: it is the third most common 
malignancy in south-central Asia. 
It can be observed that the new cases of malignant neoplasms of lip, oral cavity and 
pharynx are constantly increasing in Csongrád county due to social and environmental 
factors. In Hungary the changes are not so expressed as we experienced in case of the data of 
Csongrád county. 
 
1.3. Resistance mechanisms of cancer cells 
Drug resistance was first documented experimentally in mouse leukemic cells that 
acquired resistance to 4-amino-N10-methyl-pteroylglutamic acid in a laboratory model in 
1950. In 1973, Dano discovered active outward transport of daunomycin by drug-resistant 
cells that were cross-resistant to other chemotherapeutic agents, such as vinca alkaloids and 
other anthracyclines. Moreover, when tumour resistance developed against a single particular 
chemotherapeutic agent, in many cases the resulting phenotype shows a wide range or 
multidrug resistance pattern. The term multidrug resistance (MDR) was defined as „cellular 
resistance to anticancer agents due to a decreased concentration of active drug at the target 
sites that is caused by increased metabolism or altered transport or routing of the active drug 
species”. 
Anticancer drugs may act at different levels: cancer cells, endothelium, extracellular 
matrix, the immune system or host cells. The tumour cell can be targeted at the DNA, RNA or 
protein level. Most classical chemotherapeutic agents interact with tumour DNA, whereas 
monoclonal antibodies and small molecules are directed against proteins. The endothelium 
and extracellular matrix may be affected also by specific antibodies and small molecules. 
Classically, anticancer drugs were grouped as chemotherapy, hormonal therapy and 
immunotherapy. Chemotherapy included a number of families defined by both their chemical 
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structure and mechanism of action: alkylating agents, antibiotics, antimetabolites, 
topoisomerase I and II inhibitors, mitosis inhibitors, platinum compounds and others. 
 
1.4. The main mechanisms of drug resistance 
 
• Decrease of drug accumulation 
• Drug resistance mediated by detoxification of the drug in the cell 
• Alterations of drug targets or by enhancement of target repair 
• Alterations of genes controlling apoptosis 
 
1.5. Transporter proteins as one of the most important resistance mechanisms 
 
The principal mechanism of multidrug resistance is the active transport of drugs out of the 
cells. The transporter proteins show high specificity for their substrates, however, they have 
broad specificity for a wide range of chemically unrelated molecules. Transporters can be 
divided into different protein superfamilies based on their amino acid sequence, structure and 
evolutionary origin. 
Structures have been obtained for multidrug transporters from five distinct transporter 
superfamilies: 
1. ABC family (ATP-binding cassette transporters)  
2. RND family (resistance-nodulation-division superfamily) 
3. MFS family (major facilitator superfamily) 
4. SMR family (small multidrug resistance superfamily) 
5. MATE family (multidrug and toxic compound extrusion superfamily) 
 
1.6. The ATP-binding cassette (ABC) transporter superfamily: structure, function, 
distribution in normal tissues and in tumour cells 
 
ABC proteins have been identified in each genome sequenced, and they typically form 
large families with 30–100 members in various organisms. ABC proteins are named after a 
conserved, specific ABC domain, which can bind and hydrolyze ATP. The ABC unit (also 
called nucleotide binding domain or NBD) harbours several conserved sequence motifs. From 
NH2 to COOH terminal, these are the Walker A (P-loop), a glycine-rich sequence; a 
conserved glutamine (Q-loop), the family-specific ABC-signature (LSGGQ) motif (also called 
the C-loop), the Walker B motif, and a conserved His (His-switch). The ABC-signature motif 
is diagnostic for the family as it is present only in ABC proteins, while Walker A and B motifs 
are found in many other ATP-utilizing proteins. 
In humans, the three major types of multidrug resistance (MDR) proteins include 
members of the ABCB (ABCB1/MDR1/P-glycoprotein), the ABCC (ABCC1/MRP1, 
ABCC2/MRP2, probably also ABCC3–6, and ABCC10–11), and the ABCG 
(ABCG2/MXR/BCRP) subfamily. On the basis of a great deal of clinical and experimental 
work, it has been established that these pumps recognize a very wide range of drug substrates. 
ABCB1 preferentially extrudes large hydrophobic molecules, while ABCC1 and ABCG2 can 
transport both hydrophobic drugs and large anionic compounds, e.g., drug conjugates. 
 
1.7. Inhibition of P-glycoprotein 
 
Inhibiting P-gp and other ABC transporters has been extensively studied for more than 
two decades. The first generation of MDR modulators include many agents with different 
structure, such as calcium channel blockers, calmodulin antagonists, steroidal agents, protein 
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kinase C inhibitors, immunosuppresive drugs, antibiotics, antimalarials, psychotropic 
phenothiazines and indole alkaloids, detergents and surfactants. First-generation MDR drugs 
had other pharmacological activities and were not specifically developed for inhibiting MDR. 
Their affinity was low for ABC transporters and necessitated the use of high doses, resulting 
in high toxicity and side effects. 
Second-generation chemosensitizers were designed to reduce the side effects of the first 
generation drugs. They have better pharmacological profile, however,  they still retain some 
characteristics that limit their clinical usefulness. Many of them are substrates both for ABC 
transporters and for P450 isoenzyme 3A4. The competition between anticancer agents and 
MDR modulators for cytochrome P450 3A4 activity may result in unpredictable 
pharmacokinetic interactions. Another aspect is the well defined physiologic roles of ABC 
transporters in normal tissues (e.g. central nervous system, testes, placenta), and the inhibition 
of these transporters could reduce the ability of normal cells and tissues to protect themselves 
from cytotoxic agents. Third-generation molecules have been developed to overcome the 
limitation of the second-generation MDR modulators. They are not metabolized by 
cytochrome P450 3A4 and they do not alter the plasma pharmacokinetics of anticancer drugs. 
These agents inhibit specifically and potently the P-glycoprotein and do not inhibit other ABC 
transporters. A non-immunosuppressive cyclosporin D derivative (PSC-833; Valspodar, 
Novartis AG) was the first of these drugs to be studied, but unfortunately due to 
pharmacokinetic interactions the development of PSC-833 was discontinued. Biricodar 
(VX710), from the third-generation drugs, has been shown to reverse MDR in vitro and in 
vivo by acting on both Pgp and MRP1. Laniquidar (R101933; NCI/EORTC Inc.) and the 
substituted diarylimidazole ONT-093 (Ontogen Inc.) have a high potency and specificity for 
the P-gp transporter despite having diverse chemical structures and origins. R101933 and 
ONT-093 were shown to inhibit P-gp pump with no effect on the pharmacokinetics of 
docetaxel and paclitaxel. LY335979 is an extremely potent P-gp, and not MRP1 or MRP2, 
modulator and has a significantly lower affinity for CYP3A than for P-gp. 
 
1.8. The background of the present study 
 
Professor Joseph Molnár's research group has been working for many decades on the field of 
reversal of multidrug resistance in bacteria and cancer cells. Bacteria and cancer cells develop 
resistance to more than one agent as a consequence of being exposed to ineffective levels of 
the agent for a prolonged period of time. The resistance of these cells is mediated by 
overexpressed efflux pumps that have the ability to extrude a large variety of unrelated 
chemicals. The experimental work focused on multidrug resistance of tumour cells is based 
on development of new resistance modifiers of synthetic or natural origin. 
Various phenothiazines, benzo[a]phenothiazines and their derivatives had been tested in 
regard to different aspects. 12H-benzo[alpha]phenothiazine [M627] induced apoptosis in 
mouse lymphoma cells, in the parent cell line and in the P-glycoprotein overexpressing 
subline as well. The MDR1 gene expression of the mouse lymphoma cells (which were 
transfected with the human MDR1 gene) could be reduced by phenothiazines such as 
promethazine and trifluoperazine. 4-phenyl-3, 5-diacetyl-1, 4-dihydropyridines substituted at 
the phenyl ring were synthesized and compared for their cytotoxic activity and multidrug 
resistance (MDR)-reversing activity in in vitro assay systems. Among them, compound [G7] 
showed the highest cytotoxic activity against human promyelocytic leukemia HL-60 and 
human squamous cell carcinoma HSC-2 cells. 
Furthermore, natural compounds such as tomato lectin, feijoa peel extracts, kiwifruit peel 
extracts, Anastasia green sweet pepper, morphine alkaloids, Allium victorialis L. extracts and 
natural compounds from Euphorbia species received special consideration.  
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The main goal of Professor Molnár’s research activity is to select resistance modifiers using 
in vitro and ex vivo systems and to test the most potent compounds in in vivo experiments 
founding the base for further clinical applications. 
 
 
2. AIMS OF THE STUDY 
 
Multidrug resistance (MDR) of cancer cells can be the result of different mechanisms. One of 
the most important among them concerns altered membrane transport in tumour cells, often 
referred to as classic MDR. This mechanism is related to the overexpression of a variety of 
proteins. The main aim of this study was to look for new effective modulators of MDR1   
efflux pumps. The development of pharmacological agents that reverse multidrug resistance is 
a very promising way to overcome the difficulties in chemotherapy. 
 
The effects of MDR modulators were demonstrated at three levels: 
• The antiproliferative affect of the compounds were studied on different cancer 
and normal cells including the oral cells by MTT test 
• The modification of intracellular drug accumulation was evaluated by flow 
cytometry using rhodamine 123 accumulation assay 
• The interaction of resistance modifiers and anticancer drugs modelling 
combined chemotherapy was analysed by checkerboard microplate method 
 
The main goals of the study in details: 
1. Effect of 3-formylchromones (FC) on proliferation of tumour cells and reversal of 
multidrug resistance 
1.1. Antiproliferative effect of 3-formylchromones on human MDR1-gene transfected mouse 
lymphoma cells and MDR1-expressing human colon cancer cell line Colo 320. 
1.2. Effect of 3-formylchromones on modulation of human MDR1-gene encoded P-
glycoprotein in human MDR1-gene transfected mouse lymphoma cells and MDR1-expressing 
human colon cancer cell line Colo 320 by flow cytometry using rhodamine 123 accumulation 
assay. 
1.3. Combination of 3-formylchromones and doxorubicin using checkerboard microplate 
method on human MDR1-gene transfected mouse lymphoma cells in vitro. 
 
2. Effect of conjugated arylidene ketones on proliferation of tumour cells and reversal of 
multidrug resistance 
2.1 Antiproliferative effect of conjugated arylidene ketones on human oral cancer and human 
normal oral cells, human MDR1-gene transfected mouse lymphoma cells and MDR1-
expressing human colon cancer cell line Colo 320. 
2.2. Effect of conjugated arylidene ketones on modulation of human MDR1-gene encoded P-
glycoprotein in human MDR1-gene transfected mouse lymphoma cells and MDR1-expressing 
human colon cancer cell line Colo 320 by flow cytometry using rhodamine 123 accumulation 
assay. 
2.3. Combination of conjugated arylidene ketones and doxorubicin using checkerboard 







3. Effect of α,β-unsaturated cyclic ketones on proliferation of tumour cells and reversal of 
multidrug resistance 
3.1. Antiproliferative effect of α,β-unsaturated cyclic ketones on human oral cancer and 
human normal oral cells, human MDR1-gene transfected mouse lymphoma cells and MDR1-
expressing human colon cancer cell line Colo 320. 
3.2. Effect of α,β-unsaturated cyclic ketones on modulation of human MDR1-gene encoded 
P-glycoprotein in human MDR1-gene transfected mouse lymphoma cells. 
3.3. Combination of α,β-unsaturated cyclic ketones and doxorubicin using checkerboard 
microplate method on human MDR1-gene transfected mouse lymphoma cells and MDR1-
expressing human colon cancer cell line Colo 320 in vitro. 
 
 
3. MATERIALS AND METHODS 
 
Cell cultures:  
Human oral cancer cells (squamous cell carcinoma HSC-2, HSC-3, submandibular gland 
carcinoma HSG) and human normal oral cells (gingival fibroblast HGF, pulp cell HPC, 
periodontal ligament fibroblast HPLF) were cultured in DMEM medium supplemented with 
10% heat-inactivated FBS. Human promyelocytic leukaemia HL-60 cells were cultured in 
RPMI1640 + 10% FBS. Normal cells were prepared from the periodontal tissues, according 
to the guideline of Meikai University Ethic Committee after obtaining the informed consent 
from the patients. 
L5178 mouse T-cell lymphoma cells were transfected with pHa MDR1/A retrovirus, as 
previously described. Mdr-1- expressing cell lines were selected by culturing the infected 
cells with 60 ng/ml colchicine to maintain the expression of the MDR phenotype. L5178 
(parent) mouse T-cell lymphoma cells and the human mdr1-transfected subline were cultured 
in McCoy's 5A medium supplemented with 10% heat-inactivated horse serum, L-glutamine 
and antibiotics. Both cell lines were cultured at 37°C. The mouse lymphoma cell line was 
maintained in a 5% CO2 atmosphere. 
The human colon cancer cells (COLO320) were cultured in RPMI 1640 medium 
supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 1 mM Na-
pyruvate and 100 mM Hepes. The cell lines were incubated in a humified atmosphere (5% 
CO2, 95% air) at 37 °C. The semiadherent human colon cancer cells were detached with 
0.25% trypsin and 0.02% EDTA for 5 min at 37 °C. 
Medium: McCoy's 5A medium supplemented with 10% heat-inactivated horse serum, L-
glutamine and antibiotics; RPMI 1640 medium supplemented with 10% heat-inactivated fetal 
bovine serum, 2 mM L-glutamine, 1 mM Na-pyruvate and 100 mM Hepes. DMEM medium 
supplemented with 10% heat- inactivated FBS. 
Compounds: Rhodamine 123 (Sigma, St Louis, MO, USA); verapamil (EGIS, Hungarian 
Pharmaceutical Company, Budapest, Hungary); MTT (3-(4,5-dimethythiazol-2-yl)-2,5-
diphenyltetrazolium bromide (Sigma, St Louis, MO, USA); SDS (sodium dodecylsulfate; 
Sigma, St Louis, MO, USA); and doxorubicin (Ebewe, Austria). 3-Formylchromones 
(synthesized by Prof. Professor Noboru Motohashi, Department of Medicinal Chemistry, 
Meiji Pharmaceutical University, Tokyo, Japan), conjugated arylidene ketones (synthesized 
by Professor Jonathan Dimmock (College of Pharmacy and Nutrition, University of 
Saskatchewan, Canada), α,β-unsaturated cyclic ketones (synthesized by Professor Jonathan 
Dimmock (College of Pharmacy and Nutrition, University of Saskatchewan, Canada) 
Assay for reversal of MDR in tumour cells: The cells were adjusted to a density of 2×106/ml, 
resuspended in serum-free McCoy’s 5A medium and distributed in 0.5-ml aliquots into 
Eppendorf centrifuge tubes. The tested compounds were added at various concentrations in 
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different volumes (2.0-20.0 µl) of the 1.0-10.0 mg/ml stock solutions, and the samples were 
incubated for 10 min at room temperature. Next, 10 µl (5.2 µM final concentration) of the 
indicator rhodamine 123 was added to the samples and the cells were incubated for a further 
20 min at 37 °C, washed twice and resuspended in 0.5 ml PBS for analysis. The fluorescence 
of the cell population was measured with a Beckton Dickinson FACScan flow cytometer. 
Verapamil was used as a positive control in the rhodamine 123 exclusion experiments. The 
percentage mean fluorescence intensity was calculated for the treated MDR and parental cell 
lines as compared with the untreated cells. An activity ratio R was calculated via the 
following formula, on the basis of the measured fluorescence values: 
controlparentaltreatedparental
controlMDRtreatedMDRR =  
Assay for antiproliferative effect: The effects of increasing concentrations of the drugs alone 
and their combinations with resistance modifiers on cell growth were tested in 96-well flat-
bottomed microtiter plates. The compounds were diluted in a volume of 50 µL. Then, 1×104 
cells in 0.1 mL of medium were added to each well, with the exception of the medium control 
wells. The culture plates were further incubated at 37 °C for 72 h; at the end of the incubation 
period, 20 µL of MTT (thiazolyl blue, Sigma, St Louis, MO, USA) solution (from a 5 mg/mL 
stock) was added to each well. After incubation at 37 °C for 4 h, 100 µL of Sodium dodecyl 
sulfate (SDS) (Sigma, St Louis, MO, USA) solution (10%) was measured into each well and 
the plates were further incubated at 37 °C overnight. The cell growth was determined by 
measuring the optical density (OD) at 550 nm (ref. 630 nm) with a Dynatech MRX vertical 














A checkerboard microplate method was applied to study the effects of drug interactions 
between resistance modifiers and cytotoxic compound on cancer cells. The effects of the 
anticancer drug doxorubicin and the resistance modifiers were studied in combination on 
various cancer cell lines. The dilutions of doxorubicin (A) were made in a horizontal 
direction, and the dilutions of resistance modifiers (B) vertically in the microtiter plate in 
100µL volume. The cell suspension in the tissue culture medium was distributed into each 
well in 100 µL containing 5×104 cells. The plates were incubated for 72 h at 37 °C in a CO2 
incubator. The cell growth rate was determined after MTT staining and the intensity of the 
blue color was measured on a micro ELISA reader. Drug interactions were evaluated 
according to the following system: 
 
ID=inhibitory dose 
FIC=fractional inhibitory concentration 
FIX=fractional inhibitory index 
 
FICA= ID50A in combination / ID50A alone     
FICB= ID50B in combination / ID50B alone 
 
FIX = FICA+FICB  
FIX = 0.51-1  Additive effect 
FIX < 0.5  Synergism 
1 < FIX < 2  Indifferent effect 






1. EFFECT OF 3-FORMYLCHROMONES (FC) ON PROLIFERATION OF TUMOUR 
CELLS AND REVERSAL OF MULTIDRUG RESISTANCE  
 
1.1. Antiproliferative effect of 3-formylchromones on human MDR1-gene transfected 
mouse lymphoma cells and MDR1-expressing human colon cancer cell line Colo 320. 
When the antiproliferative effect of 3-formylchromones was measured on MDR 
mouse lymphoma cells, three different groups could be distinguished on the basis of the ID 50 
values. The ID 50 value shows the 50% inhibition of cell proliferation. In the first group, FC 
3, with an ID50=1.9µg/mL, was the most active. The compounds in the second group, FC 2, 4, 
6, 7, 8, 9, 10 and 11, were moderately active with ID50 values between 4.27-7.13. Those in the 
third group, FC 5 and FC 12-16 had very high ID50 values in the range from 21.42-79.14 
µg/mL. 
The effects of the tested compounds on the proliferation of human colon cancer cells 
were also investigated. The compounds FC 2, 3 and FC 5-10 exhibited a moderate 
antiproliferative effect, as measured on Colo 320 cells (ID50=2.02-8.70 µg/mL). 
 
1.2. Effect of 3-formylchromones on modulation of human MDR1-gene encoded P-
glycoprotein in human MDR1-gene transfected mouse lymphoma cells and MDR1-
expressing human colon cancer cell line Colo 320 by flow cytometry using rhodamine 
123 accumulation assay. 
A further investigation on the activity of the MDR efflux pump of mouse lymphoma 
cells transfected with the human MDR1 gene was also conducted. The effects of the 
compounds on the drug accumulation of the MDR cancer cells in non-toxic concentrations 
were studied using the rhodamine accumulation test. The most effective compounds proved to 
be FC 1, 3, 4, 6, 7, 8, 10 and 11. 
The effects of these compounds on the activity of the MDR efflux pump of human 
Colo 320 colon cancer cells were investigated. The most effective compounds were found to 
be FC 1, 6, 7, 8, 9, 10 and 11. 
 
1.3. Combination of 3-formylchromones and doxorubicin using checkerboard 
microplate method on human MDR1-gene transfected mouse lymphoma cells in vitro. 
From the most effective compounds, 6,8-dibromo-3-formylchromone was chosen to 
determine its interaction with the anticancer drug doxorubicin. 6,8-dibromo-3-
formylchromone was combined with doxorubicin on MDR1-gene transfected mouse 
lymphoma cells. 6,8-dibromo-3-formylchromone acted synergistically with doxorubicin on 
mouse lymphoma cells in checkerboard assay. 
 
2. EFFECT OF CONJUGATED ARYLIDENE KETONES ON PROLIFERATION OF 
TUMOUR CELLS AND REVERSAL OF MULTIDRUG RESISTANCE 
 
2.1. Antiproliferative effect of conjugated arylidene ketones on human oral cancer and 
human normal oral cells, human MDR1-gene transfected mouse lymphoma cells and 
MDR1-expressing human colon cancer cell line Colo 320. 
Thus 1a was considered a lead molecule with demonstrated cytotoxicity without short-
term marked toxicity. The main goal of Dimmock’s research group was to prepare a small 
group of prototypic molecules related to 1a with a view to determining whether selective 




All of the compounds in series 1–4 were evaluated against four neoplastic cell lines, 
namely squamous cell carcinoma HSC-2, HSC-3,  submandibular gland carcinoma HSG and 
human promyelocytic leukaemia HL-60 cells as well as the nonmalignant gingival fibroblast 
cells (HGF), pulp cells  (HPC) and periodontal ligament fibroblast cells  (HPLF). The 
average CC50 (CC50: concentration of the compound to kill 50% of the cells) of the lead 
compound 1a to HSC-2, HSC-3, HSG and HL-60 cells was 1.75 µM or 85% of the average 
potency of doxorubicin towards these four cell lines. 
 
2.2. Effect of conjugated arylidene ketones on modulation of human MDR1-gene 
encoded P-glycoprotein in human MDR1-gene transfected mouse lymphoma cells and 
MDR1-expressing human colon cancer cell line Colo 320 by flow cytometry using 
rhodamine 123 accumulation assay. 
The data revealed that 1a–c,f, 2a,b displayed a remarkable inhibition of the MDR of 
human MDR1 gene-transmitted mouse lymphoma cells. These cells overexpress the P-gp 170 
protein responsible for drug efflux. The same compounds were also the most effective on the 
elevated drug accumulation of human colon cancer Colo320 cells but in each case the FAR 
values were lower than for the murine lymphoma cells. 
 
2.3. In vitro combination of conjugated arylidene ketones and doxorubicin using 
checkerboard microplate method on human MDR1-gene transfected mouse lymphoma 
cells 
From the most effective compounds, 2b was chosen to determine its interaction with 
the anticancer drug doxorubicin. 2b was combined with doxorubicin on MDR1-gene 
transfected mouse lymphoma cells. 2b exerted indifferent effect (FIX: 1.22) with doxorubicin 
on mouse lymphoma cells in combination with doxorubicin. 
 
3.  EFFECT OF α,β-UNSATURATED CYCLIC KETONES ON PROLIFERATION OF 
TUMOUR CELLS AND REVERSAL OF MULTIDRUG RESISTANCE 
3.1. Antiproliferative effect of α,β-unsaturated cyclic ketones on human oral cancer and 
human normal oral cells, human MDR1-gene transfected mouse lymphoma cells and 
MDR1-expressing human colon cancer cell line Colo 320. 
Of the 10 compounds studied, 1, 2 and 8 showed potent antiproliferative effect on 
mouse lymphoma cells. Compound 6, 7, and 9 were moderately effective in the 
antiproliferative assay on mouse lymphoma cells. 
The proliferation of human colon cancer cells could be inhibited efficiently by compound 1, 7 
and 8. 
Based on our results, compound 1 seemed to be the most promising compound, 
because it was the most effective compound against four neoplastic cell lines such as HSC-2, 
HSC-3, HSG and HL-60 (squamous cell carcinoma HSC-2, HSC-3, submandibular gland 
carcinoma and human promyelocytic leukaemia, respectively). However, it has no effect 
against nonmalignant normal oral cells HGF, HPC and HPLF cells (gingival fibroblast, pulp 
cell, periodontal ligament fibroblast cells, respectively). 
Compound 1, 6 and 8 exerted the most effective antiproliferative effect on human MDR1 









3.2. Effect of α,β-unsaturated cyclic ketones on modulation of human MDR1-gene 
encoded P-glycoprotein in human MDR1-gene transfected mouse lymphoma cells. 
Compound 1, 6, 9 and 10 could reverse dose dependently the P-gp coupled multidrug 
resistance in mouse lymphoma cells, furthermore compound 8 has the same effect on both 
concentrations applied (4 and 40 µg/mL). 
 
3.3. Combination of α,β-unsaturated cyclic ketones and doxorubicin using checkerboard 
microplate method on human MDR1-gene transfected mouse lymphoma cells and 
MDR1-expressing human colon cancer cell line Colo 320 in vitro. 
From the most effective compounds, two compounds were chosen to determine their 
interaction with the anticancer drug doxorubicin. Compound 2,7-Bis-(3,4,5-
trimethoxyphenylmethylene)-cycloheptanone and 2,5-Bis-(3,4,5-
trimethoxyphenylmethylene)-cyclopentanone were combined with doxorubicin on MDR1-
gene transfected mouse lymphoma cells and human colon cancer cell line Colo320. 
Compound 2,7-Bis-(3,4,5-trimethoxyphenylmethylene)-cycloheptanone and 2,5-Bis-(3,4,5-
trimethoxyphenylmethylene)-cyclopentanone exerted additive effect with doxorubicin on 
mouse lymphoma cells, and surprisingly compound 2,5-Bis-(3,4,5-
trimethoxyphenylmethylene)-cyclopentanone interacted synergistically with doxorubicin 





1. EFFECT OF 3-FORMYLCHROMONES (FC) ON PROLIFERATION OF TUMOUR 
CELLS AND REVERSAL OF MULTIDRUG RESISTANCE  
 
The chromone moiety forms an important component of pharmacophores of a number 
of biologically active molecules of synthetic as well as natural origin, and many of them have 
useful medicinal applications. Chromone and coumarin derivatives are of great interest 
because of their antimicrobial, antitumour and antiviral activity. Phosphorohydrazone 
derivatives of coumarin and chromone demonstrated antitumour activity against leukemia 
L1210. Among chromone derivatives, cytotoxic activity against leukemia P388 has been 
recognized in phosphorohydrazinecarbonylic derivative. 
In our studies 3-formylchromone derivatives were investigated. It is interesting to note that 
the substituents had great influence on the antiproliferative effect. The result of the 
antiproliferative assay revealed the most effective compounds against the mouse lymphoma 
cells as FC 3, 8, 9 and 11, and against human colon cancer cells as FC 2, 5, 6, 7, 8, 9 and 10. 
There is apparently a strong structure-activity relationship between the MDR reversal activity 
and the chemical structures of the compounds studied. 
A few derivatives were able to reverse the MDR as tested the rhodamine 123 
accumulation assay. The most effective compounds against mouse lymphoma cells were FC 
1, 3, 4, 6, 7, 8, 10 and 11 , while the compounds found to be very effective against the Colo 
320 cancer cells were FC 1, 4, 6, 7, 8, 9, 10 and 11. 
We found synergism between formylchromone derivative 6,8-dibromo-3-
formylchromone and doxorubicin on mouse lymphoma cell line transfected with human 
MDR1 gene, and this result could be applied as a basis for further in vivo experiments in mice 
to improve the success of the combined chemotherapy. 
A special ground state dipole moment is probably important for the biological effect of 
the above compounds on P-glycoprotein. Additionally, the TPSA (total polar surface area) of 
the highly lipophilic compounds must be taken into consideration.  
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2. EFFECT OF CONJUGATED ARYLIDENE KETONES ON PROLIFERATION OF 
TUMOUR CELLS AND REVERSAL OF MULTIDRUG RESISTANCE 
 
The average potencies of the other compounds prepared in our study were less than 1a 
revealing that 3,4,5-trimethoxy substitution in aryl ring B was optimal (1a > 1b–f), the 
presence of ring C increases potency (1a > 2a), and a six-membered alicyclic ring was 
preferred to a five-membered one (1a > 3a). In order to obtain an answer to the first query as 
to whether preferential toxicity for malignant cells was displayed, a selectivity index (SI) 
value was calculated for each of the compounds in series 1–4.  
A review of the SI data revealed the following structure–activity relationships (SAR). 
First, marked selective potencies for malignant cells were noted in series 1 and 2, but not in 3 
and 4, indicating the importance of a six-membered rather than a five-membered alicyclic 
ring. Second, in general, the presence of ring C in series 1 enhanced selectivity since the SI 
figures of 1a,b,d–f were greater than 2a,b,d–f, respectively. Third, 1a and 2a possessed the 
highest SI figures in series 1 and 2, respectively, indicating that the 3,4,5-trimethoxy 
substitution pattern was optimal.  
1a–c,f, 2a,b displayed a remarkable inhibition of the MDR of human MDR1 gene-
transmitted mouse lymphoma cells. These cells overexpress the P-gp 170 protein responsible 
for drug efflux. The same compounds were also the most effective on the elevated drug 
accumulation of human colon cancer Colo320 cells, but in each case the FAR values were 
lower than for the murine lymphoma cells. In general, the SAR of the compounds inhibiting 
MDR were the same as the SI values generated, namely the presence of ring C was beneficial 
(1a–f > 2a–f), a six-membered alicyclic ring was preferable to the 2,5-disubstituted 
cyclopentanones (2a,d > 4a,b) and in series 1 and 2, maximum inhibition of MDR was found 
in 1a and 2a, having the 3,4,5-trimethoxy groups in ring B.  
We have to emphasize that this study of several series of compounds containing the 
1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore has led to novel, potent cytotoxins, some of 
which demonstrated remarkable selective toxicity to malignant cells and the ability to reverse 
MDR. The reasons for these important findings may have included the fact that the theory of 
sequential cytotoxicity was verified and/or preferential reduction of the nitro group took place 
in those tumours in which greater hypoxia exists. 
 
3.  EFFECT OF α,β-UNSATURATED CYCLIC KETONES ON PROLIFERATION OF 
TUMOUR CELLS AND REVERSAL OF MULTIDRUG RESISTANCE 
 
The 4-nitrophenylmethylene group is not essential for inducing MDR-reversing 
properties. Thus, replacement of this functionality in 1 by a 3,4,5-trimethoxyphenylmethylene 
group led to 6 having a similar MDR reversing potency. In fact, on occasions the 4-
nitrophenylmethylene substituent exerted a dystherapeutic effect, for example, excision of this 
group from the inactive compounds 3 and 4 led to 9 and 10, respectively, which possess MDR 
reversing properties. 
Secondly, an attempt was made to find reasons for the differences in MDR-reversing 
properties between 1 (which is an active compound) and 3 and 4 (which are devoid of this 
property).  
Thirdly, both compounds containing a sole methoxy group in aryl ring A viz. 2 and 5 
were devoid of MDR-reversing properties. 
Fourthly, all three bis compounds 6–8 reverse MDR. In particular, the remarkable 
potency of 8 establishes it as a very useful lead compound which is likely due, at least in part, 
to the favorable spatial arrangement of the 3,4,5-trimethoxyphenylmethylene groups. 
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Fifthly, removal of one of the 3,4,5-trimethoxyphenylmethylene groups of 7 yielding 9 
led to an increase in potency, suggesting that only one of these structural moieties may be 
required to confer MDR reversing properties in these compounds. 
Finally, in considering the possible structural features which may influence the 
magnitude of MDR reversal in mouse L-5178 cells, two other physicochemical parameters 
were considered. 
Compounds 6–10 are novel MDR-reversing agents which have been developed from 
the lead compound 1. In particular, the remarkable potency of 8 was discovered in this study. 
Future work will involve placing one or more 3-(3,4,5-trimethoxyphenyl)-2-propenoyl groups 
onto a variety of acyclic, alicyclic, aryl, and heteroaryl scaffolds in an attempt to find 
correlations between the topography of these molecules and potencies in this assay. Most of 
the compounds possess noteworthy cytotoxic potencies and display greater lethality to some 
neoplasms than normal cells. Activation of different caspases which induced apoptosis was 
shown in representative molecules to be at least one way whereby cytotoxicity was mediated. 
We found synergism between compound 8 and doxorubicin on Colo 320 human colon 
cancer cell line, and this result might be a promising way for combined chemotherapy of 
colon cancer patients. 
 
 
6. NEW STATEMENTS OF THE THESIS 
 
The main goal of this study was to look for new effective modulators of MDR1 efflux pumps. 
The development of pharmacological agents that reverse multidrug resistance could improve 
the efficiency of tumour chemotherapy. In our studies three groups of compounds were tested 
such as 3-formylchromones, conjugated arylidene ketones and  α,β-unsaturated cyclic ketones 
on various tumour cell lines. We found that the above mentioned compounds could be 




Chromone and coumarin derivatives are of great interest because of their biological activity. 
The pharmacological activities of many chromone derivatives such as anti-inflammatory, 
antiviral and anti-neoplastic activities have been extensively investigated. 
1.1. The results obtained in our study demonstrate that 3-formylchromones can modify the 
multidrug resistance of various cancer cells. Concerning the antiproliferative effect 3-formyl-
6-isopropylchromone was the most active compound. The compounds FC 2, 3 and FC 
5,6,7,8,9,10 exhibited a moderate antiproliferative effect on Colo 320 cells. 
1.2. A further investigation on the activity of the MDR efflux pump of mouse lymphoma cells 
transfected with the human MDR1 gene showed that some of the 3-formylchromones are 
modifiers of P-glycoprotein: the most effective compounds proved to be FC 1, 3, 4, 6, 7, 8, 10 
and 11. When the structure-activity relationship was analysed, the most effective compounds 
were those substituted at position 6 of the aromatic ring. A CH3 or NO2 group reduced the 
biological activity. A substituent Cl at position 6 and a CH3 at position 7 resulted in toxic 
compounds. A special ground state dipole moment is probably important for the biological 
effect of the above compounds on P-glycoprotein. Additionally, the TPSA (total polar surface 
area) of the highly lipophilic compounds must be taken into consideration.  
We can assume that 3-formyl-6-isopropylchromone is the most important compound, 
because it modifies the multidrug resistance in mouse lymphoma cells and in human Colo 320 
colon cancer cells as well. 3-formyl-6-isopropylchromone may represent a lead compound 
for the design of novel, safe and potent MDR chemosenzitizers. 
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1.3. Synergism was found between formylchromone derivative 6,8-dibromo-3-
formylchromone and doxorubicin on mouse lymphoma cell line transfected with human 
MDR1 gene. This information could lead to further in vivo experiments to investigate the 
combined effect of fromylchromone derivatives with different anticancer drugs. 
 
2. Conjugated arylidene ketones 
 
2.1. The cytotoxic effect of the conjugated arylidene ketones was studied and compared on 
normal oral and oral cancer cell lines. Among the arylidene ketones compounds 1a, 1b, 1e, 
2a, 2c and 2g exhibited the highest cytotoxic activity against the human oral cancer cells 
(squamous cell carcinoma HSC-2, HSC-3, submandibular gland carcinoma HSG) and HL-60 
cells. These four human tumour cell lines showed similar sensitivities to these compounds. 
On the other hand, three normal cell lines such as gingival fibroblast (HGF), pulp cell (HPC) 
and periodontal ligament fibroblast HPLF) cells were resistant to these derivatives. 
The normal cells were relatively resistant to the derivatives 1a, 1b, 1d, 1e, 2a, 2d and 2f. The 
preferential toxicity for malignant cells, the so called selective toxicity was calculated for 
each compounds. The SI values indicated that 1a, 1b, 1e, 2a, 2c and 2g had the highest 
tumour specific cytotoxic activities among the substituted arylidene ketones. 
2.2. 1a–c,f and 2a,b displayed a remarkable inhibition of the MDR of human MDR1 gene-
transmitted mouse lymphoma cells. These cells overexpress the P-gp 170 protein responsible 
for drug efflux. The same compounds were also the most effective on the elevated drug 
accumulation of human colon cancer Colo 320 cells, but in each case the FAR values were 
lower than the ones for the murine lymphoma cells. 
2.3. Marked selective potencies for malignant cells were noted in series 1 and 2, but not 3 and 
4, indicating the importance of a six-membered rather than a five-membered alicyclic ring. 
The presence of ring C in series 1 enhanced selectivity, and we proved that the 3,4,5-
trimethoxy substitution pattern was optimal for selectivity.  
We have to emphasize that this study of several series of compounds containing the 1,5-
diaryl-3-oxo-1,4-pentadienyl pharmacophore has led to novel, potent cytotoxins, some of 
which demonstrated remarkable selective toxicity to malignant cells and the ability to reverse 
MDR. 
 
3. α,β-unsaturated cyclic ketones 
 
Based on our results, compound 1 seemed to be the most promising compound, because it 
was the most effective compound against four neoplastic cell lines such as HSC-2, HSC-3, 
HSG and HL-60 (squamous cell carcinoma HSC-2, HSC-3, submandibular gland carcinoma 
and human promyelocytic leukaemia, respectively). However, it has no effect against 
nonmalignant normal oral cells HGF, HPC and HPLF cells (gingival fibroblast, pulp cell, 
periodontal ligament fibroblast cells, respectively). 
3.1. α,β-unsaturated cyclic ketone 1, 6 and 8 exerted the most effective antiproliferative effect 
on human MDR1 gene transfected mouse lymphoma cells and human colon cancer cells as 
well. 
3.2. α,β-unsaturated cyclic ketone 1, 6, 9 and 10 could reverse dose dependently the P-gp 
coupled multidrug resistance in mouse lymphoma cells. 
3.3. α,β-unsaturated cyclic ketone 7 and 8 exerted additive effect with doxorubicin on mouse 
lymphoma cells. We found synergism between compound 8 and doxorubicin on Colo 320 
human colon cancer cell line and this result might be a promising way for combined 
chemotherapy of colon cancer patients. 
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Most of the compounds possess noteworthy cytotoxic potencies and display greater lethality 
to some neoplasms than normal cells and α,β-unsaturated cyclic ketones can be recommended 





The number of new cases of cancer has increased dramatically during the last decades. Cancer 
mortality rate in Hungary is the highest in Europe, and an analysis of the past 40 years has 
revealed a worsening trend. 
Cancer cells develop resistance to more than one agent as a consequence of being exposed to 
ineffective levels of the agent for a prolonged period of time. When tumour resistance 
developed against a single particular chemotherapeutic agent, in many cases the resulting 
phenotype shows a wide range or multidrug resistance pattern. The main mechanisms of 
drug resistance of tumour cells are the following: decrease of drug accumulation by efflux 
pumps, drug resistance mediated by detoxification of the drug in the cell, alterations of drug 
targets or by enhancement of target repair, alterations of genes controlling apoptosis. 
In our studies we investigated the principal mechanism of multidrug resistance which is the 
active transport of drugs out of the cells. In tumour cell lines, multidrug resistance is often 
associated with an ATP-dependent decrease in cellular drug accumulation which was 
originally attributed to the overexpression of a single protein, the 170-kDa ABC drug 
transporter P-glycoprotein encoded by human MDR1 gene. MDR is associated with a 
reduced intracellular drug accumulation and an increased cellular drug efflux. 
The main aim of this study was to look for new effective modulators of MDR1 efflux pumps, 
which can increase the intracellular drug accumulation by modifying efflux pumps. We found 
that some of the 3-formylchromones are modifiers of P-glycoprotein, and 3-formyl-6-
isopropylchromone is the most important compound, because it modifies the multidrug 
resistance in mouse lymphoma cells and in human Colo 320 colon cancer cells as well. 
Formylchromone derivative 6,8-dibromo-3-formylchromone showed synergistic effect with 
doxorubicin on human MDR1 gene transfected mouse lymphoma cells.  Conjugated 
arylidene ketones displayed a remarkable inhibition of the MDR of human MDR1 gene-
transmitted mouse lymphoma cells. Based on our results obtained in studies with arylidene 
ketones, a new group of compounds has been developed called α,β-unsaturated cyclic 
ketones. Some α,β-unsaturated cyclic ketones exerted effective antiproliferative effect on 
human MDR1 gene transfected mouse lymphoma cells and human colon cancer cells as well, 
and they could reverse dose dependently the P-gp coupled multidrug resistance in mouse 
lymphoma cells. We found synergism between compound 2,5-Bis-(3,4,5-
trimethoxyphenylmethylene)-cyclopentanone and doxorubicin on Colo 320 human colon 
cancer cell line. 
We conclude that 3-formylchromones, conjugated arylidene ketones and α,β-unsaturated 
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